The HER2 (human epidermal growth factor receptor 2) gene is part of a family of genes that play roles in regulating cell growth. The protein it makes is a tyrosine kinase growth factor receptor that a number of normal tissues express and which probably has a role in normal cell function, regulating growth and proliferation.
Differences in growth factor (GF) signaling may cause the poor prognosis in some breast cancer cases. A new study, published in the open access journal BMC Medical Genomics, suggests that some estrogen receptor-positive breast cancers respond poorly to tamoxifen because of increased GF signaling.
A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies.
At the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), researchers from the Mayo Clinic campus in Florida report that using a combination of capecitabine, vinorelbine, and trastuzumab offers a treatment option that is at least as beneficial as other current options - and doesn't cause hair loss in patients.
Breast cancer patients who received chemotherapy prior to surgery had heightened levels of cancer-initiating stem cells in their bone marrow, and the level of such cells correlated to a tumor's lymph node involvement, according to research from The University of Texas M. D. Anderson Cancer Center.
A newly discovered gene known as DEAR1 is mutated in breast cancer and is an independent predictor of local recurrence-free survival in early-onset breast cancer, a research team headed by scientists at The University of Texas M. D. Anderson Cancer Center reports in the journal PLoS Medicine.
Alterations in the topoisomerase II alpha (TOP2A) gene were associated with better patient outcomes following anthracycline-based therapy compared with non-anthracycline-based regimens, according to a study in the April 28 online issue of the Journal of the National Cancer Institute.
AVEO Pharmaceuticals, Inc. has announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.
The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects.
Brian Rowan, Ph.D., professor of Cancer Research for the Tulane Cancer Center, is studying treatment options for an aggressive type of breast cancer that is prevalent in New Orleans among African-American women - triple-negative breast cancer.
Light directed at a breast tumor through a needle can provide pathologists with biological specifics of the tumor and help oncologists choose treatment options that would be most effective for that individual patient.
Combining a compound known as a gallium corrole with a protein carrier results in a targeted cancer therapy that is able to detect and eliminate tumors in mice with seemingly fewer side effects than other breast-cancer treatments, says a team of researchers from the California Institute of Technology (Caltech), the Israel Institute of Technology (Technion) and the Cedars-Sinai Medical Center.
For women with recurrent breast cancer, the treatment the doctor chooses is usually based on the properties of their original breast cancer.
Bavarian Nordic today provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy of metastatic breast cancer patients whose tumours over-express HER2.
A set of 50 genes can be used to reliably identify the four known types of breast cancer, according to research conducted at Washington University School of Medicine in St. Louis and collaborating institutions.
Several studies had previously suggested that regular physical exercise reduces the breast cancer risk of women.
Good quality extra-virgin olive oil contains health-relevant chemicals, 'phytochemicals', that can trigger cancer cell death.
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.
Researchers have developed a new type of imaging compound that allows them to visualize viable breast cancer cells that have spread to the lungs in mice.
Findings published in the December 1, 2008, issue of Clinical Cancer Research , a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit.
Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites.